SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
A phase 3 trial testing IMA203 in melanoma, now recruiting.
Overview
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma is a phase 3 interventional study registered as NCT06743126, led by Immatics US, and recruiting when checked on 2026-09-11. Official title: A Prospective, Multicenter, Open-label, Randomised, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301). Planned enrolment is 360 participants (estimated). The study started in 2025-01-14 and primary completion is expected in 2028-01. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma
Shares Melanoma and the tag ctgov-ingest.
- TrialA Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Shares Melanoma and the tag ctgov-ingest.
- TrialSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma
Shares Melanoma and the tag ctgov-ingest.
- TrialIO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Shares Melanoma and the tag ctgov-ingest.
- TrialA Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Shares Melanoma and the tag ctgov-ingest.
- TrialA Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
Shares Melanoma and the tag ctgov-ingest.
- TreatmentBA3071
Shares Melanoma and the tag ctgov-ingest.
- TreatmentTRK-950
Shares Melanoma and the tag ctgov-ingest.